Sun Pharmaceutical Industries Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on July 31, 2025
SUNPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Sun Pharma has filed the Notice of its 33rd Annual General Meeting scheduled for July 31, 2025 at 4:00 PM IST via video conferencing, along with the Annual Report for FY2024-25. The cut-off date for e-voting eligibility is July 24, 2025, and remote e-voting runs from July 27 to July 30, 2025. The Annual Report highlights strong FY25 performance: consolidated revenue grew 9% to ₹520 billion, EBITDA rose 17.3% to ₹153 billion, and adjusted net profit increased 19% to ₹120 billion, with the Global Specialty business growing 17.1% to US$ 1,216 million. Key business updates include the US FDA approval of Leqselvi for alopecia areata, the May 2025 acquisition of Checkpoint Therapeutics (adding Unloxcyt to its onco-dermatology portfolio), and a global licensing deal with Philogen for cancer immunotherapy Fibromun. The company also flagged ongoing US FDA compliance issues at three facilities (Halol, Mohali, Dadra) and held a net cash position of about US$ 3.1 billion as of March 31, 2025.
Routine regulatory filing with no immediate material impact on the stock. The detailed annual report gives investors a clear view of FY25 financials, growth outlook (mid-to-high single-digit revenue growth expected in FY26), and key risks such as US facility compliance issues. Shareholders should review the AGM agenda and voting items ahead of July 31.